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Conventional aortic valve replacement for severe aortic stenosis is associated with a high operative mortality in the 
elderly patients with significant comorbidities, including severe respiratory dysfunction, renal insufficiency, and 
compromised cardiac function. Human transcatheter aortic valve implantation was first reported in 2002 and has 
become a valid alternative in selected high­risk patients in Europe and North America. This article describes the 
first attempt of transfemoral transcatheter aortic valve implantation in Korea. The procedure was applied in two 
consecutive patients with severe aortic stenosis. Despite several intra­operative complications during procedure, 
the post­operative outcomes were good for both patients. At post­operative 30 days there was satisfactory prosthetic 
valve function and hemodynamic stability. (Korean J Anesthesiol 2011; 60: 128­133)
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    Conventional aortic valve replacement (AVR) is the definitive 
treatment for severe aortic stenosis (AS). If untreated and 
symptoms of angina, syncope, or heart failure are allowed to 
develop, the average survival is 2 to 3 years, with a high risk of 
sudden death [1]. However, conventional AVR is associated 
with a high risk of operative mortality in elderly patients 
with significant comorbidities such as, severe respiratory 
dysfunction, renal insufficiency, and compromised cardiac 
function [2]. Therefore, the development of minimally invasive 
therapeutic options is comsidered important. The clinical 
use of transcatheter aortic valve implantation (TAVI) was first 
reported in 2002 [3]. TAVI is now considered a valid alternative 
to conventional surgery in selected high­risk patients in Europe 
and North America. The present report describes the first 
attempt of transfemoral TAVI in Korea and 30­day follow­up.
Case Reports
Case 1
    An 83­year old woman with severe AS was scheduled for 
TAVI. She had had dyspnea on exertion (NYHA class III) for 129 www.ekja.org
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10 years, and this had aggravated recently. Her past history 
included hypertension, pulmonary tuberculosis when younger, 
and percutaneous coronary stent insertion in the left anterior 
descending artery (LAD), left circumflex artery (LCX), and 
right coronary artery (RCA) 5 months ago. She has taken 
aspirin 100 mg, clopidogrel 75 mg, and diltiazem 90 mg daily, 
and all of these medications were continued. Transthoracic 
echocardiography showed severe AS with an aortic valve area 
(AVA) of 0.8 cm
2, a mean pressure gradient of 41 mmHg and an 
aortic annulus diameter of 21 mm. Mild mitral regurgitation 
(MR) was present and the left ventricular ejection fraction 
was 62%. Coronary angiography (CAG) showed that all stents 
were patent. Computed tomography (CT) showed diffuse 
calcification in the abdominal aorta and no tortuosity in either 
common iliac artery. The right iliac artery was 13.2 mm and 
the right femoral artery was 8.9 mm in diameter. The logistic 
EuroSCORE was 14.3%.
    The procedure was performed in the cardiac catheterization 
laboratory under general anesthesia. A 5­lead electrocardio­
graph, pulse oximeter, BIS sensor, and two cerebral oxymetry 
sensors were applied. Anesthesia was induced with etomidate 
12 mg, rocuronium 50 mg, and continuous infusion of remifen­
tanil (target effect site concentration 10 ng/ml) and propofol 
(target effect site concentration 1.0 μg/ml) using a target con­
trolled infusion system (Orchestra
Ⓡ, Fresenius vial, Brezims, 
France). An intra­arterial catheter was inserted into the left 
radial artery and endotracheal intubation was performed. A 
central venous catheter (MAC
TM Two­Lumen Central Venous 
Access set, ARROW
Ⓡ, Reading, PA, USA) with a Swan­Ganz 
catheter (Swan­Ganz CCOmbo, CCO/SvO2/CEDV, Edwards 
lifesciences LLC, Irvine, CA, USA) was inserted into the right 
internal jugular vein for continuous monitoring of cardiac 
output and mixed venous oxygen saturation using continuous 
cardiac output monitoring (Vigilance
Ⓡ, Edwards lifesciences 
LLC, Irvine, CA, USA). During the procedure, anesthesia was 
maintained with oxygen (2 L/min), and continuous infusion 
of remifentanil (target effect site concentration 10-20 ng/
ml), propofol (target effect site concentration 1.0-1.5 μg/ml) 
and rocuronium 0.5 μg/ml/min. Two external defibrillator 
pads were attached. Transesophageal echocardiography 
(TEE) (Live 3D TEE, iE33, Philips ultrasound, Bothell, WA, 
USA) was performed to confirm the aortic annulus diameter 
and to provide images for correct valve positioning during the 
procedure. Heparin (1 mg/kg) was given to achieve an activated 
coagulation time > 250 seconds. The left femoral vein was used 
for the placement of a pacing wire (Electrophysiology catheter, 
St. Jude Medical
Ⓡ, St. Paul, MN, USA) in the right ventricular 
apex and the left femoral artery was used for insertion of a 
pigtail catheter in the aortic root. Surgical exposure of the right 
femoral artery was performed and a 12 French introducer was 
inserted. Balloon valvuloplasty was successfully performed 
under rapid ventricular pacing (RVP) of 200 beats/min (Dual 
chamber temporary pacemaker, Medtronic
Ⓡ, Minneapolis, 
MN, USA) (Fig. 1). The duration of cardiac standstill during RVP 
was less than 10 seconds. Blood pressure and cardiac rhythm 
were restored well after RVP. Systolic blood pressure was 110-
140 mmHg and diastolic blood pressure was 50-60 mmHg 
before and after RVP. The 12 French sheath was exchanged 
with a 24 French introducer sheath. Althought preoperative 
CT indicated that the right femoral artery was large enough for 
a 24 French introducer, it was a tight fit during the procedure, 
and insertion required the cardiologist to exert more force 
than anticipated. A 23 mm Edward­Sapien valve (Edwards 
Lifesciences LLC, Irvine, CA, USA) crimped onto a balloon was 
then advanced into the aortic annulus. The optimal prosthetic 
valve position was confirmed using TEE and fluoroscopy. The 
balloon was inflated after RVP. However, the prosthetic valve 
was ejected into the ascending aorta and moved down to the 
descending thoracic aorta. TEE was performed immediately 
and showed that the valve was packed in the descending 
thoracic aorta. However, there was no flow disturbance around 
the valve and the vital signs were stable. The cardiologist 
made a decision to leave the valve in place and insert another 
valve. The second valve crimped onto a balloon was advanced 
through the embolized valve. RVP was repeated several times 
to enable correct positioning and intermittent bolus injections 
of phenylephrine (100 μg/ml) were used without continuous 
infusion of a vasopressor. The second trial was successful. TEE 
Fig. 1. Changes of electrocardiogram (lead V and lead II) and 
arterial blood pressure before and after rapid ventricular pacing. 
Arrow: commencement of rapid ventricular pacing, Dotted arrow: 
termination of rapid ventricular pacing.130 www.ekja.org
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showed that the valve was stable and there was no paravalvular 
leakage. A root aortogram showed patent coronary arteries 
and no paravalvular leakage or aortic regurgitation (AR) (Fig. 2). 
After confirmation of valve function, the cardiac surgeon tried 
to remove the 24 French introducer, but initially found that 
it would not move in any direction. After approximately 30 
minutes of manipulation, the surgeon was able to move the 
introducer backward. At that time, the mean arterial pressure 
abruptly decreased to 30 mmHg. Angiography was performed 
and showed a right external iliac artery rupture. Packed red 
blood cells and colloid solutions were rapidly infused. The 
cardiologist inserted the balloon catheter into the descending 
aorta and inflated the balloon. A vascular surgeon performed 
an emergecy laparotomy and clamped the proximal side of 
the right external iliac artery. The patient was then sent to the 
operating room. The 24 French introducer was removed (Fig. 3) 
and an emergency femorofemoral bypass was performed. The 
total infused fluid volume was 14 units of packed red blood 
cells, 10 units of fresh frozen plasma, 10 units of platelets, 1,500 
ml of cell saver blood, 4,400 ml of crystalloid solutions and 1,000 
ml of colloid solutions. On post­operative day 1, the patient was 
mentally alert, had good motor and sensory nerve function, and 
a normal pulse in her right lower extremity. Echocardiography 
showed a well­functioning prosthetic aortic valve, a mean 
pressure gradient of 16 mmHg, mild paravalvular leakage 
and mild AR. Chest radiography showed no migration of the 
embolized valve (Fig. 4). The patient was extubated on post­
operative day 2 and sent to the general ward. The prosthetic 
aortic valve was functioning stable, however, the patient had 
ileus till post­operative day 30.
Case 2
    An 84­year old woman with severe AS was scheduled for 
TAVI. Her past history included hypertension, pulmonary 
tuberculosis when younger, and intermediate stenosis of LAD 
and LCX. She has taken aspirin 100 mg, isosorbide dinitrate 
40 mg, and atenolol 50 mg daily, and all of these medications 
were continued. Transthoracic echocardiography showed 
severe AS with an AVA of 0.8 cm
2, a mean pressure gradient of 
40 mmHg and an aortic annulus diameter of 21.5 mm. Mild AR 
and mild MR were present. The left ventricular ejection fraction 
was 66% and mild to moderate atherosclerosis was present in 
Fig. 2. Root aortogram after deployment of prosthetic aortic valve 
shows patent coronary arteries and no aortic regurgitation. T: 
transesopahgeal echocardiography probe, V: prosthetic aortic valve, 
P: pacemaker wire.
Fig. 3. The 24 French introducer sheath after removal. A segment of 
the external iliac artery is torn out with the sheath. Fig. 4. Follow-up chest radiograph shows no movement of embolized 
valve. E: embolized prosthetic valve, V: prosthetic valve.131 www.ekja.org
Korean J Anesthesiol Son, et al.
the descending thoracic aorta and aortic arch. CAG showed 
70-80% stenosis at the distal LAD and distal LCX. CT showed 
patent non­tortuous iliac and femoral arteries (the right iliac 
artery was 8.5 mm and right femoral artery was 7.3 mm in 
diameter). The logistic EuroSCORE was 6.14%.
    The anesthetic preparation was identical as that for case 
1. Isosorbide dinitrate 1.0 μg/kg/min was continuously 
infused after induction. Heparin (1 μg/kg) was given to 
achieve an activated coagulation time > 250 seconds. Balloon 
valvuloplasty was successfully performed under RVP. Blood 
pressure and cardiac rhythm were restored well after RVP. 
Systolic blood pressure was 90-120 mmHg and diastolic blood 
pressure was 50-60 mmHg before and after RVP. However, ST 
segment elevation was observed in lead II and V, and worsened 
after repeated RVP. The infusion rate of isosorbide dinitrate 
was therefore increased and intermittent bolus injections of 
phenylephrine (100 μg/ml) were used. Prosthetic aortic valve 
implantation was successfully performed and ST segment 
elevation improved to the normal range. TEE showed a stable 
valve position and no paravalvular leakage (Fig. 5). A root 
aortogram showed patent coronary arteries and trace AR. After 
confirmation of valve function, a new­onset left bundle branch 
block was observed. The 24 French introducer was easily 
removed. The procedure took a total of 105 minutes. The patient 
was extubated uneventfully and sent to the ICU. Although she 
occasionally complained of chest discomfort without pain, 
electrocardiography and cardiac enzymes findings remained 
normal, and the symptoms resolved within 3 hours. The 
isosorbide dinitrate infusion was ceased, and she continued 
on her pre­operative oral medications with the addition of 
clopidogrel 75 mg. The patient was sent to the general ward on 
post­operative day 1, and showed no signs of complications. 
Echocardiography showed a satisfactorily functioning 
prosthetic aortic valve, a mean pressure gradient of 21 mmHg 
and mild AR. The patient was well at 30­day follow­up. 
Discussion
    Although conventional AVR is the gold standard treatment for 
symptomatic severe AS, and operative mortality is low in ideal 
candidates, its use is limited in the elderly with comorbidities 
[2]. Percutaneous balloon valvuloplasty was initially designed 
to treat valve stenosis less invasively. However, stenosis typically 
returns within 6 months following valvuloplasty [4]. Hence, 
TAVI was developed, and has been widely performed in selected 
high­risk patients, mainly in Europe and North America. 
The advantages of TAVI include avoidance of a sternotomy, 
cardiopulmonary bypass and cardiac arrest, along with a short 
hospital stay and fast return to functional status [5].
    Recent National Institute for Health and Clinical Excellence 
(NICE) guidelines and licensing regulations have restricted 
the use of TAVI to selected patients not suitable for surgical 
AVR due to high operative mortality and risk of severe 
complications [6]. The EuroSCORE is usually used as a 
predictive risk model [2] and TAVI is recommended in patients 
with a logistic EuroSCORE over 20%. Comprehensive baseline 
examination and careful patient selection is important to 
avoid complications at implantation. Patients underwent 
transthoracic echocardiography, coronary and aortofemoral 
angiography, and a multidetector CT to confirm adequate 
vascular dimensions and lack of tortuosity or intravascular 
thrombus. There are several contraindications of TAVI, which 
may change as the technology develops. These include bicuspid 
aortic valve (because the altered anatomy makes secure 
placement of the transcatheter valve which are potentially 
unstable), previous mechanical AVR, endocarditis, recent 
myocardial infarction or cerebrovascular accident, moderate to 
severe mitral or tricuspid valve regurgitation, left ventricular or 
atrial thrombus, an aortic annular diameter less than 18 mm or 
over 25 mm, an ascending aorta diameter over 45 mm, severe 
vascular calcification and aortic disease [7]. 
    A hybrid operation room (a standard operation room with 
an additional angiography system equivalent to a standard 
catheterization laboratory) is recommended for the TAVI as 
a precaution for emergency such as device embolization, 
prolonged ventricular fibrillation, and massive hemorrhage. 
In our cases, the procedure was performed in the cardiac 
catheterization laboratory with operating room­like sterile 
precautions. A cardiac surgeon took active part in the 
procedure, and a vascular surgeon was on call and aware of 
the ongoing procedure. A perfusionist was present to institute 
emergency CPB. The anesthesiologist took a participatory role 
in monitoring and standards of care in the catheterization 
Fig. 5. Mid esophageal AV long axis view shows a stable valve 
position and no paravalvular leakage.132 www.ekja.org
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laboratory for this procedure.
    General anesthesia or local anesthesia plus sedation can be 
used. Elective general anesthesia has many advantages, which 
includes facilitation of sheath placement, removal, and eventual 
surgical repair of the arterial access site, immobility during 
valve deployment, periprocedural TEE, airway management, 
minimal patient movement, avoidance of breathing artifacts, 
and rapid CPB institution when necessary [8]. Anesthetic 
preparation is identical to that for open cardiac surgery. 
Short­acting anesthetics are used to facilitate emergence and 
extubation at the end of the procedure. 
    The complication rates associated with TAVI have yet to be 
determined. Reported complications include poor recovery of 
cardiac function after RVP, paravalvular leakage, AR, myocardial 
ischemia and device embolization, complete heart block, new­
onset arrhythmia, neurological dysfunction or stroke, damage 
to the vascular access site, and radiocontrast induced acute 
renal failure [7]. RVP and cessation of mechanical ventilation 
interrupt cardiac ejection and minimize cardiac motion, 
facilitating exact prosthesis positioning within the native 
annulus. After termination of RVP, heart rate, rhythm, and 
arterial blood pressure usually return to baseline, but a bolus 
injection of a vasopressor or defibrillation may be required to 
restore stable hemodynamics. Both present patients showed 
stable hemodynamics after RVP. Intermittent bolus injections 
of phenylephrine (100 μg/ml) were used without continuous 
infusion of norepinephrine in both patients. Phenylephrine or 
norepinephrine is adequate for increasing systemic vascular 
resistance. Catecholamines such as epinephrine may worsen 
hypotension when administered to patients with left ventricular 
hypertrophy [9] and should be used with caution. The second 
present patient with intermediate coronary artery disease 
showed aggravation of ST segment elevation despite continuous 
isosorbide dinitrate infusion. That means deterioration of 
coronary artery flow after RVP. Therefore, it is necessary to 
consider the underlying coronary status and allow for sufficient 
rest periods of 1-2 minutes after RVP. Paravalvular regurgitation 
is often present immediately after valve deployment, but 
improves after 24-48 hours as valve morphology alters at body 
temperature [7]. Reinflation of the deployment balloon within 
the prosthesis or further expansion of the valve within the 
annulus is often employed for treatment of paravalvular AR. 
Significant AR suggests overexpansion of the prosthesis, which 
may require deployment of a second prosthetic valve within the 
first one [10]. Prosthetic valve embolization occurred in the first 
present case. We assumed it was the result of the insufficient 
cardiac standstill. To prevent this, a few seconds of delay for 
non­pulsatile flow through the aortic valve may be required. 
Previous reports documented that valve embolization has been 
experienced during initial attempts with the procedure [10]. 
Management of this complication requires repositioning of 
the prosthesis, implantation of an additional valve prosthesis, 
or an emergency sternotomy, CPB, aortic cross­clamping, 
and aortotomy to remove the embolized valve and perform 
open AVR [10]. Vascular injury at the access site is the most 
common complication and causes sudden and significant 
hemorrhage. Anesthesiologists should be alert to the possibility 
of a major vascular rupture, which requires urgent repair. To 
minimize the risk of this complication, careful evaluation of 
the arterial anatomy is necessary and the diameter of both the 
femoral and iliac arteries should be large enough for introducer 
sheath insertion. Also, those arteries should be free of severe 
calcification and not be tortous. In the first present case, 
althought the femoral and iliac arteries were considered large 
enough, sheath insertion was found to be difficult due to intra­
arterial calcification. We assumed that rupture of the common 
iliac artery occurred due to forceful insertion and removal of the 
sheath. The introducer sheath should be inserted and removed 
smoothly, and if it becomes stuck as our case, it should be 
removed in the operating room with preparation for emergency. 
    Systemic anticoagulation should be commence before TAVI 
and continue postoperatively. Usually, administering aspirin 
300 mg and clopidogrel 300 mg before the procedure and 
starting regular dose of aspirin 100 mg and clopidogrel 75 mg, 
soon after the end of the procedure, are recommended [8]. 
These are normally continued for 3-6 months. If a patient 
has been medicated as in our cases, loading dose of aspirin 
and clopidogrel are not necessary. Patients who re­present 
after TAVI for non­cardiac surgery can be managed similarly 
to patients after conventional AVR. There is no evidence that 
discontinuing anti­platelet drugs increases the risk of valve 
thrombosis perioperatively, and full heparinization is not 
required [7]. 
    Although the procedure is still in its infancy and long­
term outcomes are not yet known, the results from the first 
generation have been encouraging, demonstrating satisfactory 
technical feasibility, substantial reduction of the transaortic 
pressure gradient, and fast left ventricular function recovery [11]. 
Previous reports demonstrated that perioperative mortality and 
in­hospital mortality were 0-6% and 6.7-12%, respectively, 
and that there was no evidence of structural device failure 
during 2 year follow­up [7,10,11]. 
    In conclusion, TAVI has become an alternative to surgical AVR 
for the elderly with comorbidities who have a high operative 
mortality rate or are deemed non­operable. However, judicious 
selection of patients is important because TAVI can cause 
several serious complications. A multidisciplinary approach 
including a trained cardiac surgeon, interventional cardiologist, 
and cardiac anesthesiologist and a hybrid operation room 
is essential to provide safe and successful service. Anesthe­133 www.ekja.org
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siologists must be aware of entire procedure and be prepared 
for sudden hemodynamic deterioration, which may require 
inotropic support, defibrillation, massive fluid infusion, or 
emergency surgery. 
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